Suzhou Immunofoco Biotechnology Co., Ltd

This early-phase study is testing a new cell therapy called IMV102 in patients with multiple myeloma that has returned or stopped responding to other treatments. The research will check if the treatment is safe and if it helps control the cancer. About 30 patients who have alread…

This early-stage study is testing a new cell therapy called IMV101 in adults whose B-cell non-Hodgkin lymphoma has come back or hasn't responded to at least two prior treatments. The main goals are to find a safe dose and see if the therapy shows early signs of fighting the cance…

This study is testing whether a new targeted treatment called IMC002 works better than standard options for people with advanced stomach cancer that has a specific marker called CLDN18.2. It's for patients whose cancer has continued to grow despite trying at least two other treat…